Alkermes plc

29.71+0.1500+0.51%Vol 2.21M1Y Perf 20.55%
Jun 24th, 2022 16:00 DELAYED
BID29.41 ASK33.00
Open29.69 Previous Close29.56
Pre-Market- After-Market29.71
 - -  - -%
Target Price
30.40 
Analyst Rating
Moderate Buy 2.44
Potential %
2.32 
Finscreener Ranking
★★     44.59
Insiders Trans % 3/6/12 mo.
-100/-88/-71 
Value Ranking
★+     42.90
Insiders Value % 3/6/12 mo.
-100/-100/-96 
Growth Ranking
★+     43.11
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-96 
Income Ranking
 —    -
Price Range Ratio 52W %
72.02 
Earnings Rating
Strong Buy
Market Cap4.88B 
Earnings Date
27th Jul 2022
Alpha-0.01 Standard Deviation0.11
Beta0.75 

Today's Price Range

29.3930.21

52W Range

21.2433.00

5 Year PE Ratio Range

-33.90-17.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
5.99%
1 Month
2.98%
3 Months
8.31%
6 Months
23.33%
1 Year
20.55%
3 Years
36.41%
5 Years
-49.19%
10 Years
83.40%

TickerPriceChg.Chg.%
ALKS29.710.15000.51
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.70
2.20
0.27
0.39
-5.80
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
48.20
-4.70
1.80
-10.70
-5.13
RevenueValueIndustryS&P 500US Markets
1.20B
7.32
1.38
6.75
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.140.01107.14
Q04 2021-0.030.13533.33
Q03 2021-0.05-0.0260.00
Q02 2021-0.020.13750.00
Q01 2021-0.210.01104.76
Q04 2020-0.04-0.05-25.00
Q03 2020-0.140.12185.71
Q02 2020-0.13-0.0838.46
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.120.00-
9/2022 QR-0.1814.29Positive
12/2022 FY-0.6013.04Positive
12/2023 FY-0.0756.25Positive
Next Report Date27th Jul 2022
Estimated EPS Next Report-0.12
Estimates Count4
EPS Growth Next 5 Years %25.10
Volume Overview
Volume2.21M
Shares Outstanding164.14K
Shares Float124.09M
Trades Count17.45K
Dollar Volume65.86M
Avg. Volume1.61M
Avg. Weekly Volume1.85M
Avg. Monthly Volume1.40M
Avg. Quarterly Volume1.57M

Alkermes plc (NASDAQ: ALKS) stock closed at 29.71 per share at the end of the most recent trading day (a 0.51% change compared to the prior day closing price) with a volume of 2.21M shares and market capitalization of 4.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2245 people. Alkermes plc CEO is Richard F. Pops.

The one-year performance of Alkermes plc stock is 20.55%, while year-to-date (YTD) performance is 27.73%. ALKS stock has a five-year performance of -49.19%. Its 52-week range is between 21.24 and 33, which gives ALKS stock a 52-week price range ratio of 72.02%

Alkermes plc currently has a PE ratio of -73.80, a price-to-book (PB) ratio of 4.28, a price-to-sale (PS) ratio of 3.83, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of -3.20%, a ROC of -3.68% and a ROE of -5.80%. The company’s profit margin is -5.13%, its EBITDA margin is 1.80%, and its revenue ttm is $1.20 Billion , which makes it $7.32 revenue per share.

Of the last four earnings reports from Alkermes plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Alkermes plc’s next earnings report date is 27th Jul 2022.

The consensus rating of Wall Street analysts for Alkermes plc is Moderate Buy (2.44), with a target price of $30.4, which is +2.32% compared to the current price. The earnings rating for Alkermes plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alkermes plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alkermes plc has a Buy technical analysis rating based on Technical Indicators (ADX : 8.90, ATR14 : 1.22, CCI20 : 88.36, Chaikin Money Flow : 0.07, MACD : 0.00, Money Flow Index : 53.79, ROC : 2.63, RSI : 58.14, STOCH (14,3) : 86.21, STOCH RSI : 1.00, UO : 52.64, Williams %R : -13.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alkermes plc in the last 12-months were: Blair C. Jackson (Option Excercise at a value of $827 483), Blair C. Jackson (Sold 49 999 shares of value $1 480 335 ), Brian P. Mckeon (Buy at a value of $264 269), Brian P. Mckeon (Option Excercise at a value of $0), Christian Todd Nichols (Option Excercise at a value of $0), Christian Todd Nichols (Sold 7 474 shares of value $211 203 ), Craig C. Hopkinson (Option Excercise at a value of $0), Craig C. Hopkinson (Sold 14 289 shares of value $354 692 ), David A. Daglio (Option Excercise at a value of $0), David Joseph Gaffin (Option Excercise at a value of $231 700), David Joseph Gaffin (Sold 14 000 shares of value $364 000 ), David W. Anstice (Option Excercise at a value of $292 000), David W. Anstice (Sold 20 000 shares of value $491 504 ), Emily Peterson Alva (Buy at a value of $49 861), Emily Peterson Alva (Option Excercise at a value of $0), Frank Anders Wilson (Option Excercise at a value of $0), Iain M. Brown (Option Excercise at a value of $662 000), Iain M. Brown (Sold 40 000 shares of value $1 199 600 ), Michael J. Landine (Option Excercise at a value of $1 655 000), Michael J. Landine (Sold 100 000 shares of value $2 853 270 ), Nancy J. Wysenski (Option Excercise at a value of $0), Nancy L. Snyderman (Buy at a value of $10 005), Nancy L. Snyderman (Option Excercise at a value of $0), Richard B. Gaynor (Option Excercise at a value of $0), Richard F. Pops (Option Excercise at a value of $7 447 499), Richard F. Pops (Sold 347 257 shares of value $9 717 783 ), Shane M. Cooke (Option Excercise at a value of $827 500), Shane M. Cooke (Sold 50 000 shares of value $1 434 375 ), Wendy L. Dixon (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (33.33 %)
3 (33.33 %)
2 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (55.56 %)
5 (55.56 %)
5 (62.50 %)
Moderate Sell
1 (11.11 %)
1 (11.11 %)
1 (12.50 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.44
Moderate Buy
2.44
Hold
2.63

Alkermes plc

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

CEO: Richard F. Pops

Telephone: +353 17728000

Address: 1 Burlington Road, Dublin D04 C5Y6, , IE

Number of employees: 2 245

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

77%23%

Bearish Bullish

73%27%

Bearish Bullish

67%33%

TipRanks News for ALKS

Thu, 28 Apr 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Achieve Life Sciences (ACHV)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and BioSig Technologies (BSGM)

- TipRanks. All rights reserved.

Fri, 22 Apr 2022 11:47 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Danaher (DHR) and Jazz Pharmaceuticals (JAZZ)

- TipRanks. All rights reserved.

Thu, 21 Apr 2022 22:16 GMT Alkermes (ALKS) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Thu, 17 Feb 2022 09:20 GMT Alkermes (ALKS) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 13:46 GMT Alkermes (ALKS) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 12:40 GMT Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), ProQR (PRQR) and Ovid Therapeutics (OVID)

- TipRanks. All rights reserved.

News

Stocktwits